IL173036A0 - Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors - Google Patents
Quinoline and quinazoline derivatives having affinity for 5ht1-type receptorsInfo
- Publication number
- IL173036A0 IL173036A0 IL173036A IL17303606A IL173036A0 IL 173036 A0 IL173036 A0 IL 173036A0 IL 173036 A IL173036 A IL 173036A IL 17303606 A IL17303606 A IL 17303606A IL 173036 A0 IL173036 A0 IL 173036A0
- Authority
- IL
- Israel
- Prior art keywords
- quinoline
- affinity
- quinazoline derivatives
- type receptors
- receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0316915.8A GB0316915D0 (en) | 2003-07-18 | 2003-07-18 | Compounds |
| PCT/EP2004/008000 WO2005014552A1 (en) | 2003-07-18 | 2004-07-15 | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL173036A0 true IL173036A0 (en) | 2006-06-11 |
Family
ID=27764115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL173036A IL173036A0 (en) | 2003-07-18 | 2006-01-09 | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US7279481B2 (en) |
| EP (3) | EP1876174B1 (en) |
| JP (1) | JP2006528146A (en) |
| KR (1) | KR20060041242A (en) |
| CN (1) | CN100441571C (en) |
| AR (1) | AR046394A1 (en) |
| AT (2) | ATE448205T1 (en) |
| AU (1) | AU2004263268B2 (en) |
| BR (1) | BRPI0412695A (en) |
| CA (1) | CA2532452A1 (en) |
| CY (1) | CY1107974T1 (en) |
| DE (2) | DE602004012564T2 (en) |
| DK (1) | DK1646613T3 (en) |
| ES (2) | ES2302543T3 (en) |
| GB (1) | GB0316915D0 (en) |
| HK (1) | HK1089438A1 (en) |
| HR (1) | HRP20080226T3 (en) |
| IL (1) | IL173036A0 (en) |
| IS (1) | IS2744B (en) |
| MA (1) | MA27926A1 (en) |
| MX (1) | MXPA06000716A (en) |
| NO (1) | NO20060774L (en) |
| NZ (1) | NZ544586A (en) |
| PL (1) | PL1646613T3 (en) |
| PT (1) | PT1646613E (en) |
| RU (1) | RU2402533C2 (en) |
| SI (1) | SI1646613T1 (en) |
| TW (1) | TW200521115A (en) |
| WO (1) | WO2005014552A1 (en) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| MXPA06014495A (en) * | 2004-06-17 | 2007-03-01 | Cytokinetics Inc | Substituted urea derivatives for treating cardiac diseases. |
| KR100817538B1 (en) * | 2006-07-05 | 2008-03-27 | 한국화학연구원 | Novel Substituted-1?-quinazoline-2,4-dione derivatives, preparation method thereof and pharmaceutical composition containing the same |
| CA2673481A1 (en) * | 2006-12-19 | 2008-06-26 | University Of Virginia Patent Foundation | Combined effects of topiramate and ondansetron on alcohol consumption |
| WO2008095086A2 (en) * | 2007-01-31 | 2008-08-07 | University Of Virginia Patent Foundation | Topiramate plus naltrexone for the treatment of addictive disorders |
| ATE499099T1 (en) | 2007-07-19 | 2011-03-15 | Esteve Labor Dr | SUBSTITUTED TETRAHYDRO-QUINOLINE SULPHONAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICATIONS |
| CA2697990A1 (en) * | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
| NZ588037A (en) | 2008-02-28 | 2012-08-31 | Univ Virginia Patent Found | Serotonin transporter gene SLC6A4 and treatment of alcoholism |
| WO2009132202A2 (en) | 2008-04-24 | 2009-10-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| ES2358718T3 (en) * | 2008-05-06 | 2011-05-13 | Biedermann Motech Gmbh | IMPLANT IN THE FORM OF VARILLA, IN CONCRETE FOR THE DYNAMIC STABILIZATION OF THE VERTEBRAL COLUMN. |
| US20100298397A1 (en) * | 2009-05-19 | 2010-11-25 | Singh Nikhilesh N | Method of treatment of obsessive compulsive disorder with ondansetron |
| CN101671336B (en) | 2009-09-23 | 2013-11-13 | 辽宁利锋科技开发有限公司 | Aromatic heterocyclic pyridine derivatives and analogs and preparation method and application thereof |
| EP2308850A1 (en) * | 2009-10-06 | 2011-04-13 | Laboratorios Del. Dr. Esteve, S.A. | Heterocycyl-substituted-alkylamino phenyl derivatives, their preparation and use as medicaments |
| UA116615C2 (en) | 2010-07-02 | 2018-04-25 | Юніверсіті Оф Вірджінія Петент Фаундейшн | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence |
| AP2014007488A0 (en) | 2011-08-09 | 2014-03-31 | Takeda Pharmaceutical | Cyclopropaneamine compound |
| CA2848211A1 (en) | 2011-09-09 | 2013-03-14 | University Of Virginia Patent Foundation | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| WO2013169964A1 (en) * | 2012-05-09 | 2013-11-14 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| CN103508927A (en) * | 2012-06-25 | 2014-01-15 | 天津药物研究院 | Method for preparing 2-methanesulfonyl amino diphenyl ether |
| CN105051005B (en) | 2012-10-12 | 2017-06-13 | 武田药品工业株式会社 | Cyclopropylamine compound and application thereof |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| KR102305244B1 (en) | 2013-11-20 | 2021-09-27 | 우베 고산 가부시키가이샤 | Novel 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purposes |
| AR099994A1 (en) | 2014-04-11 | 2016-08-31 | Takeda Pharmaceuticals Co | CYCLOPROPANAMINE COMPOUND AND ITS USES |
| WO2016075314A1 (en) | 2014-11-13 | 2016-05-19 | Institut National De La Recherche Agronomique | Identification of yarrowia lipolytica transcription factors that affect protein production |
| FR3028527A1 (en) | 2014-11-13 | 2016-05-20 | Pivert | IDENTIFICATION OF TRANSCRIPTION FACTORS OF YARROWIA LIPOLYTICA |
| WO2016102951A1 (en) | 2014-12-23 | 2016-06-30 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| ME02997B (en) | 2014-12-23 | 2018-10-20 | 4D Pharma Res Ltd | A bacteroides thetaiotaomicron strain and its use in reducing inflammation |
| MD3307288T2 (en) | 2015-06-15 | 2019-12-31 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| PL3206700T3 (en) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| CN115364122A (en) | 2015-06-15 | 2022-11-22 | 4D制药研究有限公司 | Compositions comprising bacterial strains |
| MA41010B1 (en) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA41060B1 (en) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| EA034677B1 (en) | 2015-11-20 | 2020-03-05 | 4Д Фарма Рисёрч Лимитед | Compositions for treating or preventing cancer comprising enterococcus gallinarum strain |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| DK3313423T3 (en) | 2016-03-04 | 2019-05-20 | 4D Pharma Plc | COMPOSITIONS INCLUDING BACTERIAL BLAUTIA STAMPS FOR TREATMENT OF VISCERAL HYPERSENSITIVITY |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| TWI802545B (en) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | Compositions comprising bacterial strains |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| LT3630136T (en) | 2017-05-22 | 2021-06-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| IL283973B (en) | 2017-06-14 | 2022-08-01 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| EP3638271B1 (en) | 2017-06-14 | 2020-10-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| HUE052258T2 (en) | 2017-06-14 | 2021-04-28 | 4D Pharma Res Ltd | Compositions comprising a bacterial strain of the genus megasphaera and uses thereof |
| CN108047143A (en) * | 2017-12-18 | 2018-05-18 | 刘凤娟 | A kind of synthetic method for the 5-hydroxytryptamine receptor antagonist for being used to treat Functional Gastrointestinal Disease |
| PT3814347T (en) | 2018-06-27 | 2023-07-18 | Bristol Myers Squibb Co | Naphthyridinone compounds useful as t cell activators |
| HUE064531T2 (en) | 2018-06-27 | 2024-04-28 | Bristol Myers Squibb Co | Substituted naphthyridinone compounds useful as t cell activators |
| AR119821A1 (en) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | SUBSTITUTED PYRIDOPYRIMIDINOL COMPOUNDS USEFUL AS T-CELL ACTIVATORS |
| AR120823A1 (en) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T-CELL ACTIVATORS |
| CN118308475A (en) * | 2024-03-18 | 2024-07-09 | 安徽医科大学第一附属医院 | Application of HTR1B as diagnosis marker of embryo development arrest and treatment target |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2641602A (en) | 1950-11-29 | 1953-06-09 | Eastman Kodak Co | 1, 8-dihydroxy-5-nitro-4-hydroxyethylphenyl aminoanthraquinone compounds |
| US3992537A (en) | 1971-06-07 | 1976-11-16 | Boehringer Ingelheim Gmbh | Pharmaceutical compositions containing an N-phenyl-imidazolidine-2-one and method of use |
| US3975525A (en) | 1971-06-07 | 1976-08-17 | Boehringer Ingelheim Gmbh | N-[4'-Imidazolidinon-(2)-yl-phenethyl]-N'-pyridyl-piperazines and salts thereof |
| US3937708A (en) | 1971-06-07 | 1976-02-10 | Boehringer Ingelheim Gmbh | N-phenyl-imidazolidine-1-ones |
| JPS5883677A (en) | 1981-11-11 | 1983-05-19 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
| US4891275A (en) * | 1982-10-29 | 1990-01-02 | Norsk Hydro A.S. | Aluminum shapes coated with brazing material and process of coating |
| JPS6354363A (en) | 1986-08-26 | 1988-03-08 | Ss Pharmaceut Co Ltd | Quinoline derivative |
| FI95572C (en) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt |
| US4933447A (en) | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| US4891375A (en) | 1988-01-13 | 1990-01-02 | Pfizer Inc. | Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds |
| JP2777159B2 (en) | 1988-12-22 | 1998-07-16 | エーザイ株式会社 | Pharmaceuticals containing cyclic amine derivatives |
| GB9300195D0 (en) | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
| GB9300194D0 (en) | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
| GB9308725D0 (en) | 1993-04-27 | 1993-06-09 | Wyeth John & Brother Ltd | Piperazine derivatives |
| CA2250347C (en) * | 1996-03-29 | 2006-02-21 | Duphar International Research B.V. | Piperazine and piperidine compounds with high affinity for dopamine-d2 and serotonin-5ht1a receptors |
| WO1997041108A1 (en) | 1996-04-30 | 1997-11-06 | Warner-Lambert Company | Substituted piperazines and piperidines as central nervous system agents |
| GB2312843A (en) | 1996-05-07 | 1997-11-12 | Merck & Co Inc | Method of treating rheumatoid arthritis |
| WO1998025617A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| DE69819266T2 (en) | 1997-09-02 | 2004-07-29 | Duphar International Research B.V. | Piperidine and piperazine derivatives as 5-HT1 receptor agonists |
| EP0900792B1 (en) * | 1997-09-02 | 2003-10-29 | Duphar International Research B.V | Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists |
| WO1999021834A1 (en) | 1997-10-27 | 1999-05-06 | Neurosearch A/S | Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors |
| WO1999031086A1 (en) * | 1997-12-12 | 1999-06-24 | Smithkline Beecham Plc | Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists |
| UA62015C2 (en) * | 1998-12-28 | 2003-12-15 | Pfizer Prod Inc | Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants) |
| AU5567000A (en) | 1999-06-24 | 2001-01-09 | Toray Industries, Inc. | Alpha1b-adrenergic receptor antagonists |
| ES2234683T3 (en) * | 1999-11-05 | 2005-07-01 | Smithkline Beecham Plc | ISOQUINOLINE AND QUINAZOLINE DERIVATIVES WITH COMBINED ACTIVITY ON THE 5HT1A, 5HT1B AND 5HT1D RECEPTORS. |
| US6939871B2 (en) | 2000-10-26 | 2005-09-06 | Smithkline Beecham P.L.C. | Benzoxazinone derivatives, their preparation and use |
| CA2364211A1 (en) | 2000-12-05 | 2002-06-05 | Phillip Branch Chappell | Combination treatment for depression, anxiety and psychosis |
| GB0106419D0 (en) * | 2001-03-15 | 2001-05-02 | Smithkline Beecham Plc | Novel compounds |
| MY140679A (en) | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
| GB0203804D0 (en) | 2002-02-18 | 2002-04-03 | Glaxo Group Ltd | Compounds |
| GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| JP2006508101A (en) | 2002-11-08 | 2006-03-09 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Phenylalkyl and pyridylalkylpiperazine derivatives |
| GB0227240D0 (en) * | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| US6759435B1 (en) * | 2003-07-03 | 2004-07-06 | A.P. Group Inc. | Antidepressant drugs and methods |
| GB0316915D0 (en) * | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| WO2005087742A1 (en) | 2004-03-08 | 2005-09-22 | Exelixis, Inc. | Metabolic kinase modulators and methods of use as pesticides |
| NZ549254A (en) | 2004-03-10 | 2010-06-25 | Nycomed Gmbh | Amido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors |
| PE20060653A1 (en) | 2004-08-31 | 2006-09-27 | Glaxo Group Ltd | CONDENSED TRICYCLIC DERIVATIVES AS 5-HT1 RECEIVER MODULATORS |
-
2003
- 2003-07-18 GB GBGB0316915.8A patent/GB0316915D0/en not_active Ceased
-
2004
- 2004-07-15 AT AT07118193T patent/ATE448205T1/en not_active IP Right Cessation
- 2004-07-15 ES ES04763307T patent/ES2302543T3/en not_active Expired - Lifetime
- 2004-07-15 PL PL04763307T patent/PL1646613T3/en unknown
- 2004-07-15 NZ NZ544586A patent/NZ544586A/en unknown
- 2004-07-15 DE DE602004012564T patent/DE602004012564T2/en not_active Expired - Lifetime
- 2004-07-15 SI SI200430699T patent/SI1646613T1/en unknown
- 2004-07-15 MX MXPA06000716A patent/MXPA06000716A/en active IP Right Grant
- 2004-07-15 ES ES07118193T patent/ES2336148T3/en not_active Expired - Lifetime
- 2004-07-15 RU RU2006104993/04A patent/RU2402533C2/en not_active IP Right Cessation
- 2004-07-15 CA CA002532452A patent/CA2532452A1/en not_active Abandoned
- 2004-07-15 AT AT04763307T patent/ATE389637T1/en active
- 2004-07-15 DE DE602004024141T patent/DE602004024141D1/en not_active Expired - Lifetime
- 2004-07-15 WO PCT/EP2004/008000 patent/WO2005014552A1/en active IP Right Grant
- 2004-07-15 US US10/565,066 patent/US7279481B2/en not_active Expired - Fee Related
- 2004-07-15 EP EP07118193A patent/EP1876174B1/en not_active Expired - Lifetime
- 2004-07-15 PT PT04763307T patent/PT1646613E/en unknown
- 2004-07-15 CN CNB2004800270575A patent/CN100441571C/en not_active Expired - Fee Related
- 2004-07-15 DK DK04763307T patent/DK1646613T3/en active
- 2004-07-15 EP EP09175186A patent/EP2145622A1/en not_active Withdrawn
- 2004-07-15 EP EP04763307A patent/EP1646613B1/en not_active Expired - Lifetime
- 2004-07-15 AU AU2004263268A patent/AU2004263268B2/en not_active Ceased
- 2004-07-15 KR KR1020067001103A patent/KR20060041242A/en not_active Application Discontinuation
- 2004-07-15 JP JP2006520756A patent/JP2006528146A/en not_active Ceased
- 2004-07-15 BR BRPI0412695-5A patent/BRPI0412695A/en not_active IP Right Cessation
- 2004-07-16 TW TW093121227A patent/TW200521115A/en unknown
- 2004-07-16 AR ARP040102527A patent/AR046394A1/en not_active Application Discontinuation
-
2006
- 2006-01-09 IL IL173036A patent/IL173036A0/en unknown
- 2006-01-18 MA MA28738A patent/MA27926A1/en unknown
- 2006-02-15 IS IS8304A patent/IS2744B/en unknown
- 2006-02-17 NO NO20060774A patent/NO20060774L/en not_active Application Discontinuation
- 2006-09-01 HK HK06109772A patent/HK1089438A1/en not_active IP Right Cessation
-
2007
- 2007-03-16 US US11/687,098 patent/US7459456B2/en not_active Expired - Fee Related
-
2008
- 2008-05-23 HR HR20080226T patent/HRP20080226T3/en unknown
- 2008-05-29 CY CY20081100555T patent/CY1107974T1/en unknown
- 2008-07-02 US US12/166,547 patent/US7592346B2/en not_active Expired - Fee Related
-
2009
- 2009-08-13 US US12/540,452 patent/US7732600B2/en not_active Expired - Fee Related
-
2010
- 2010-04-23 US US12/766,053 patent/US20100204273A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1089438A1 (en) | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | |
| GB0322409D0 (en) | Quinazoline derivatives | |
| IL174534A0 (en) | Quinazoline derivatives | |
| IL164324A0 (en) | Quinolinone derivatives | |
| HK1091489A1 (en) | Quinazoline derivatives | |
| HK1091479A1 (en) | Quinazoline derivatives | |
| HK1111417A1 (en) | Quinazoline derivatives | |
| GB0215823D0 (en) | Quinazoline derivatives | |
| GB0321648D0 (en) | Quinazoline derivatives | |
| IL164299A0 (en) | Radiolabelled quinoline and quinolinone derivatives and their use as metaboropic glutamate receptor ligands | |
| IL175421A0 (en) | Quinazoline derivatives | |
| IL174397A0 (en) | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | |
| IL172467A0 (en) | Quinolyl amide derivatives as ccr-5 antagonists | |
| IL174390A0 (en) | Quinazoline derivatives | |
| GB0330002D0 (en) | Quinazoline derivatives | |
| AU2002215043A1 (en) | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | |
| ZA200603039B (en) | Quinazoline derivatives | |
| PL374817A1 (en) | Quinazoline derivatives | |
| GB0321620D0 (en) | Quinazoline derivatives | |
| AU2002310838A1 (en) | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | |
| AU2002308138A1 (en) | 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | |
| GB0322460D0 (en) | Quinazoline derivatives | |
| GB0322410D0 (en) | Quinazoline derivatives | |
| GB0317664D0 (en) | Quinazoline derivatives | |
| GB0309870D0 (en) | Quinazoline derivatives |